Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Halis Akturk to Diabetes Mellitus, Type 1

This is a "connection" page, showing publications Halis Akturk has written about Diabetes Mellitus, Type 1.

 
Connection Strength
  
 
 
12.630
  
  1. Akturk HK. Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes. Endocrinol Metab Clin North Am. 2026 Sep; 55(3):515-524.
    View in: PubMed
    Score: 0.289
  2. Akturk HK, Karakus KE, Chen B, Walker TC. Exploring the Relationship Between Newly Defined Continuous Glucose Monitoring (CGM) Metrics and the Standard CGM Metrics in 30,000 People with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):264-270.
    View in: PubMed
    Score: 0.286
  3. Akturk HK, Karakus KE, Cengiz D, Mason E, Beck E, Kaur G, Garg SK. Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):193-200.
    View in: PubMed
    Score: 0.286
  4. Akturk HK, Mason E, Cengiz D, Karakus KE, Garg SK. Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2026 Jun; 28(6):614-618.
    View in: PubMed
    Score: 0.286
  5. Riddell MC, Parkin CG, Turner LV, Akturk HK. Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations. Diabetes Technol Ther. 2026 Feb; 28(1_suppl):31S-37S.
    View in: PubMed
    Score: 0.284
  6. Akturk HK, Perkins BA, Dunn TC. Clinical Trials in Diabetes: Examining the Value of Use of Continuous Dual Glucose-Ketone Monitoring. Diabetes Technol Ther. 2025 11; 27(S4):S44-S50.
    View in: PubMed
    Score: 0.279
  7. Akturk HK, Brown SA, Beck RW, Sherr JL, Bergenstal RM, Kovatchev BP, Vigersky R, Breton MD, Hovorka R, Klonoff DC, Garg SK. Registration and Real-Life Studies on Automated Insulin Delivery Systems. J Diabetes Sci Technol. 2025 07; 19(4):924-936.
    View in: PubMed
    Score: 0.272
  8. Akturk HK, Brown SA, Beck RW, Sherr JL, Bergenstal RM, Kovatchev BP, Vigersky R, Breton MD, Hovorka R, Klonoff DC, Garg SK. Registration and Real-Life Studies on Automated Insulin Delivery Systems. Diabetes Technol Ther. 2025 07; 27(S3):S48-S59.
    View in: PubMed
    Score: 0.272
  9. Mason E, Karakus KE, Akturk HK. Barriers to glucagon use in patients with type 1 diabetes. Prim Care Diabetes. 2025 06; 19(3):341-343.
    View in: PubMed
    Score: 0.267
  10. Karakus KE, Snell-Bergeon J, Mason E, Akturk HK. Improvement in Newly Defined Continuous Glucose Monitor Metrics, Extended Hypoglycemia, and Extended Hyperglycemia With Automated Insulin Delivery Initiation in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2026 May; 20(3):721-726.
    View in: PubMed
    Score: 0.262
  11. Karakus KE, Snell-Bergeon JK, Akturk HK. Comparison of Computational Statistical Packages for the Analysis of Continuous Glucose Monitoring Data with a Reference Software, "Ambulatory Glucose Profile," in Type 1 Diabetes. Diabetes Technol Ther. 2025 03; 27(3):202-208.
    View in: PubMed
    Score: 0.260
  12. Akturk HK. Access to Diabetes Care Should Be a Universal Right for People With Type 1 Diabetes: Lessons Learned From the Norwegian Childhood Diabetes Registry. Diabetes Care. 2024 07 01; 47(7):1111-1113.
    View in: PubMed
    Score: 0.254
  13. Akturk HK, Michel K, Couts K, Karakus KE, Robinson W, Michels A. Routine Blood Glucose Monitoring Does Not Predict Onset of Immune Checkpoint Inhibitor-Induced Type 1 Diabetes. Diabetes Care. 2024 03 01; 47(3):e29-e30.
    View in: PubMed
    Score: 0.248
  14. Akturk HK, Battelino T, Castañeda J, Arrieta A, van den Heuvel T, Cohen O. Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Technol Ther. 2024 03; 26(S3):102-106.
    View in: PubMed
    Score: 0.248
  15. Akturk HK. Limitations of 14-Day Continuous Glucose Monitoring Sampling for Assessment of Hypoglycemia and Glycemic Variability in Type 1 Diabetes. Diabetes Technol Ther. 2024 07; 26(7):503-508.
    View in: PubMed
    Score: 0.248
  16. Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN. Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study. J Diabetes Sci Technol. 2025 Mar; 19(2):292-296.
    View in: PubMed
    Score: 0.247
  17. Akturk HK, Sakamoto C, Vigers T, Shah VN, Pyle L. Minimum Sampling Duration for Continuous Glucose Monitoring Metrics to Achieve Representative Glycemic Outcomes in Suboptimal Continuous Glucose Monitor Use. J Diabetes Sci Technol. 2025 Mar; 19(2):345-351.
    View in: PubMed
    Score: 0.241
  18. Akturk HK, McKee AM. Emerging Technologies and Therapeutics for Type 1 Diabetes. Endocrinol Metab Clin North Am. 2024 03; 53(1):81-91.
    View in: PubMed
    Score: 0.239
  19. Akturk HK, Snell-Bergeon J, Karakus KE, Shah VN. Assessing the relationship between low-calorie sweetener use and quality of life measures in adults with type 1 diabetes. BMC Endocr Disord. 2023 Jul 11; 23(1):147.
    View in: PubMed
    Score: 0.237
  20. Karakus KE, Shah VN, Klonoff D, Akturk HK. Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes. Diabetes Obes Metab. 2023 11; 25(11):3144-3151.
    View in: PubMed
    Score: 0.237
  21. Akturk HK, Snell-Bergeon J, Shah VN. Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes. Diabetes Technol Ther. 2022 10; 24(10):779-783.
    View in: PubMed
    Score: 0.221
  22. Akturk HK, Herrero P, Oliver N, Wise H, Eikermann E, Snell-Bergeon J, Shah VN. Impact of Different Types of Data Loss on Optimal Continuous Glucose Monitoring Sampling Duration. Diabetes Technol Ther. 2022 10; 24(10):749-753.
    View in: PubMed
    Score: 0.221
  23. Akturk HK, Snell-Bergeon J, Shah VN. Health Care Professionals' Perspectives on Use of Diabetes Technologies for Managing Visually Impaired Patients With Diabetes. J Diabetes Sci Technol. 2023 11; 17(6):1610-1613.
    View in: PubMed
    Score: 0.220
  24. Akturk HK, Snell-Bergeon J, Kinney GL, Champakanath A, Monte A, Shah VN. Differentiating Diabetic Ketoacidosis and Hyperglycemic Ketosis Due to Cannabis Hyperemesis Syndrome in Adults With Type 1 Diabetes. Diabetes Care. 2022 02 01; 45(2):481-483.
    View in: PubMed
    Score: 0.215
  25. Akturk HK, Vigers T, Forlenza G, Champakanath A, Pyle L. Comparison of Cgmanalysis, a Free Open-Source Continuous Glucose Monitoring Data Management and Analysis Software, with Commercially Available CGM Platforms: Data Standardization for Diabetes Technology Research. Diabetes Technol Ther. 2022 01; 24(1):54-60.
    View in: PubMed
    Score: 0.213
  26. Akturk HK, Snell-Bergeon J, Pyle L, Fivekiller E, Garg S, Cobry E. Accuracy of a breath ketone analyzer to detect ketosis in adults and children with type 1 diabetes. J Diabetes Complications. 2021 11; 35(11):108030.
    View in: PubMed
    Score: 0.209
  27. Akturk HK, Shah VN. Gastric Emptying Abnormalities in Diabetes Mellitus. N Engl J Med. 2021 08 05; 385(6):575-576.
    View in: PubMed
    Score: 0.208
  28. Akturk HK, Agarwal S, Hoffecker L, Shah VN. Inequity in Racial-Ethnic Representation in Randomized Controlled Trials of Diabetes Technologies in Type 1 Diabetes: Critical Need for New Standards. Diabetes Care. 2021 06; 44(6):e121-e123.
    View in: PubMed
    Score: 0.205
  29. Akturk HK, Dowd R, Shankar K, Derdzinski M. Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features. Diabetes Technol Ther. 2021 03; 23(S1):S21-S26.
    View in: PubMed
    Score: 0.202
  30. Acciaroli G, Welsh JB, Akturk HK. Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. J Diabetes Sci Technol. 2022 05; 16(3):677-682.
    View in: PubMed
    Score: 0.200
  31. Akturk HK, Michels AW. Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. Curr Opin Endocrinol Diabetes Obes. 2020 08; 27(4):187-193.
    View in: PubMed
    Score: 0.194
  32. Akturk HK, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes. Diabetes Technol Ther. 2021 01; 23(1):81-83.
    View in: PubMed
    Score: 0.194
  33. Akturk HK, Michels AW. Immune Checkpoint Inhibitor-Induced Type 1 Diabetes: An Underestimated Risk. Mayo Clin Proc. 2020 03; 95(3):614-615.
    View in: PubMed
    Score: 0.188
  34. Akturk HK, Brackett S. A Novel and Easy Method to Locate and Remove First Approved Long-Term Implantable Glucose Sensors. Diabetes Technol Ther. 2020 07; 22(7):538-540.
    View in: PubMed
    Score: 0.188
  35. Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020 04; 22(4):583-589.
    View in: PubMed
    Score: 0.186
  36. Polsky S, Akturk HK. Case series of a hybrid closed-loop system used in pregnancies in clinical practice. Diabetes Metab Res Rev. 2020 03; 36(3):e3248.
    View in: PubMed
    Score: 0.186
  37. Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2019 09; 36(9):1075-1081.
    View in: PubMed
    Score: 0.180
  38. Akturk HK, Taylor DD, Camsari UM, Rewers A, Kinney GL, Shah VN. Association Between Cannabis Use and Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes. JAMA Intern Med. 2019 Jan 01; 179(1):115-118.
    View in: PubMed
    Score: 0.174
  39. Akturk HK, Alkanani A, Zhao Z, Yu L, Michels AW. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity. J Clin Endocrinol Metab. 2018 10 01; 103(10):3589-3592.
    View in: PubMed
    Score: 0.171
  40. Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 10; 20(10):639-647.
    View in: PubMed
    Score: 0.170
  41. Akturk HK, Rewers A, Garg SK. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018 08; 25(4):246-250.
    View in: PubMed
    Score: 0.169
  42. Garg SK, Akturk HK. A New Era in Continuous Glucose Monitoring: Food and Drug Administration Creates a New Category of Factory-Calibrated Nonadjunctive, Interoperable Class II Medical Devices. Diabetes Technol Ther. 2018 06; 20(6):391-394.
    View in: PubMed
    Score: 0.167
  43. Garg SK, Rewers AH, Akturk HK. Ever-Increasing Insulin-Requiring Patients Globally. Diabetes Technol Ther. 2018 06; 20(S2):S21-S24.
    View in: PubMed
    Score: 0.167
  44. Akturk HK. Management of Type 1 diabetes should be different from Type 2 diabetes at hospital admission. Diabet Med. 2018 06; 35(6):824.
    View in: PubMed
    Score: 0.167
  45. Akturk HK, Rewers A, Joseph H, Schneider N, Garg SK. Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes. Diabetes Technol Ther. 2018 06; 20(S2):S224-S232.
    View in: PubMed
    Score: 0.167
  46. Garg SK, Rewers AH, Akturk HK. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2018 02; 20(S1):S139-S153.
    View in: PubMed
    Score: 0.163
  47. Akturk HK, Shah VN. Severe Hypoglycemia in Adults With Type 1 Diabetes After Switching to Insulin Degludec. J Diabetes Sci Technol. 2018 05; 12(3):733-734.
    View in: PubMed
    Score: 0.161
  48. Garg SK, Akturk HK. The Future of Continuous Glucose Monitoring. Diabetes Technol Ther. 2017 06; 19(S3):S1-S2.
    View in: PubMed
    Score: 0.155
  49. Akturk HK, Yasa S. Previously unreported abnormalities in Wolfram Syndrome Type 2. Pediatr Endocrinol Diabetes Metab. 2017; 23(2):107-110.
    View in: PubMed
    Score: 0.151
  50. Karakus KE, Clayton MG, Baschal EE, McDaniel KA, Yu L, Haider Z, Polsky S, Akturk HK, Gottlieb PA, Garg SK, Michels AW. Differences in Clinical Manifestations and Islet Autoantibodies by Age in Adult-Onset Type 1 Diabetes. Diabetes Care. 2026 07 01; 49(7):1194-1201.
    View in: PubMed
    Score: 0.073
  51. Karakus KE, Akturk HK, Kruger D, Ahmann A, Bharvaga A, Langel CR, Ackeifi CA, Rosen J, Pyle L, Snell-Bergeon JK, Shah VN. Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis. Diabetes Care. 2026 May 01; 49(5):718-723.
    View in: PubMed
    Score: 0.072
  52. Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug; 4(8):EVIDoa2500173.
    View in: PubMed
    Score: 0.068
  53. Mann EA, Rompicherla S, Miyazaki B, Rioles N, Hardison H, Golden L, Sarhis J, Akturk HK, Lee J, DeSalvo DJ, Gomez P, Ebekozien O, Prahalad P. Early Continuous Glucose Monitor Use in Children and Adolescents With Type 1 Diabetes: Rates of Initiation and Impact on Glycemic Outcomes. Diabetes Care. 2025 May 01; 48(5):768-775.
    View in: PubMed
    Score: 0.067
  54. Garg SK, Bailey TS, Castorino K, Christiansen MP, Liljenquist DR, Salazar H, Akturk HK, Gao S, Johnson ML, Beck SE. Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes. Diabetes Technol Ther. 2025 06; 27(6):430-438.
    View in: PubMed
    Score: 0.067
  55. Hirsch IB, Beck RW, Marak MC, Kudva Y, Akturk HK, Bhargava A, Codorniz K, Diner J, Aleppo G, Blevins T, Levy CJ, Raskin P, Castorino K, Manessis A, Pickering D, Steenkamp DW, Weinstock RS, Bode BW, Hamdy O, Nguyen QT, Kipnes M, Ruedy KJ, Desjardins D, Haider Z, Jacobson C, Lee S, Buse JB, Klein KR, O'Malley G, Church MM, Mottalib A, Baran JD, Kurek C, Rizvi S, Donahue C, Tamarez D, Atakov Castillo A, Borgman S, Frey S, Calhoun P. A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes. Diabetes Care. 2025 Mar 01; 48(3):353-360.
    View in: PubMed
    Score: 0.067
  56. Beck RW, Bailey RJ, Akturk HK, Rizvi S, Kudva Y, Blevins T, Church MM, Manessis A, Calhoun P, Ruedy KJ, Hirsch IB. A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 03; 27(3):161-169.
    View in: PubMed
    Score: 0.067
  57. Karakus KE, Akturk HK, Snell-Bergeon JK, Shah VN. Progression of Diabetic Retinopathy After Initiation of Automated Insulin Delivery System in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2026 Jul; 20(4):1159-1163.
    View in: PubMed
    Score: 0.066
  58. Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 01; 27(1):1-9.
    View in: PubMed
    Score: 0.066
  59. Brown SA, Laffel LM, Akturk HK, Forlenza GP, Shah VN, Wadwa RP, Cobry EC, Isganaitis E, Schoelwer M, Lu VS, Rueda R, Sherer N, Corbett JP, Sasson-Katchalski R, Pinsker JE. Randomized, Crossover Trial of Control-IQ Technology with a Lower Treatment Range and a Modified Meal Bolus Module in Adults, Adolescents, Children, and Preschoolers with Varying Levels of Baseline Glycemic Control. Diabetes Technol Ther. 2025 03; 27(3):187-193.
    View in: PubMed
    Score: 0.065
  60. Shah VN, Peters AL, Umpierrez GE, Sherr JL, Akturk HK, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs PG, Lal RA, Mader JK, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho CN, Ayers AT, Tian T, Aaron RE, Klonoff DC. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. J Diabetes Sci Technol. 2025 01; 19(1):191-216.
    View in: PubMed
    Score: 0.065
  61. Hirsch IB, Beck RW, Marak MC, Calhoun P, Mottalib A, Salhin A, Manessis A, Coviello AD, Bhargava A, Thorsell A, Atakov Castillo A, Bode BW, Levister C, Levy CJ, Donahue C, Cordero C, Beatson C, Langel CR, Jacobson C, Kurek C, Cruse D, Pickering D, Tamarez D, Steenkamp DW, Desjardins D, Aleppo G, O'Malley G, Akturk HK, Diner J, Baran JD, Buse JB, Ruedy K, Codorniz K, Klein KR, Castorino K, Jordan LF, Kipnes M, Church MM, Hamdy O, Raskin P, Nguyen QT, Weinstock RS, Lee S, Rizvi S, Bzdick S, Ghorbani Rodriguez T, Salah T, Blevins T, Kudva YC, Haider Z. A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of Insulin or Automated Insulin Delivery. Diabetes Care. 2024 09 01; 47(9):1682-1687.
    View in: PubMed
    Score: 0.064
  62. Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 06; 26(6):367-374.
    View in: PubMed
    Score: 0.063
  63. Klein MP, Akturk HK, Snell-Bergeon JK, Shah VN. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. 2025 Mar; 19(2):297-303.
    View in: PubMed
    Score: 0.063
  64. Carlson AL, Graham TE, Akturk HK, Liljenquist DR, Bergenstal RM, Sulik B, Shah VN, Sulik M, Zhao P, Briggs P, Sassan-Katchalski R, Pinsker JE. Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial. J Diabetes Sci Technol. 2024 11; 18(6):1288-1292.
    View in: PubMed
    Score: 0.062
  65. Shah VN, Kanapka LG, Akturk HK, Polsky S, Forlenza GP, Kollman C, Beck RW, Snell-Bergeon JK. Time in Range Is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study. Diabetes Technol Ther. 2024 04; 26(4):246-251.
    View in: PubMed
    Score: 0.062
  66. Shah VN, Akturk HK, Trahan A, Piquette N, Wheatcroft A, Schertz E, Carmello K, Mueller L, White K, Fu L, Sassan-Katchalski R, Messer LH, Habif S, Constantin A, Pinsker JE. Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ Technology. J Diabetes Sci Technol. 2024 11; 18(6):1281-1287.
    View in: PubMed
    Score: 0.062
  67. Ebekozien O, Mungmode A, Sanchez J, Rompicherla S, Demeterco-Berggren C, Weinstock RS, Jacobsen LM, Davis G, McKee A, Akturk HK, Maahs DM, Kamboj MK. Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016-2022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technol Ther. 2023 11; 25(11):765-773.
    View in: PubMed
    Score: 0.060
  68. Karakus KE, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade. Diabetes Care. 2023 09 01; 46(9):1646-1651.
    View in: PubMed
    Score: 0.060
  69. Peter ME, Rioles N, Liu J, Chapman K, Wolf WA, Nguyen H, Basina M, Akturk HK, Ebekozien O, Perez-Nieves M, Poon JL, Mitchell B. Prevalence of fear of hypoglycemia in adults with type 1 diabetes using a newly developed screener and clinician's perspective on its implementation. BMJ Open Diabetes Res Care. 2023 07; 11(4).
    View in: PubMed
    Score: 0.059
  70. Alonso GT, Triolo TM, Akturk HK, Pauley ME, Sobczak M, Forlenza GP, Sakamoto C, Pyle L, Frohnert BI. Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population. Diabetes Care. 2023 06 01; 46(6):1218-1222.
    View in: PubMed
    Score: 0.059
  71. Shah VN, Akturk HK, Vigers T, Pyle L, Oliver N, Klonoff DC. Relationship Between Daytime Versus Nighttime Continuous Glucose Monitoring Metrics with A1C in Adults with Type 1 Diabetes. Diabetes Technol Ther. 2023 01; 25(1):62-68.
    View in: PubMed
    Score: 0.057
  72. Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 10; 28(10):2092-2099.
    View in: PubMed
    Score: 0.056
  73. Xu NY, Nguyen KT, Krouwer JS, Akturk HK, Shah VN, Klonoff DC. Retained Diabetes Devices-A Literature Review. J Diabetes Sci Technol. 2023 11; 17(6):1676-1685.
    View in: PubMed
    Score: 0.055
  74. Xu NY, Nguyen KT, DuBord AY, Pickup J, Sherr JL, Teymourian H, Cengiz E, Ginsberg BH, Cobelli C, Ahn D, Bellazzi R, Bequette BW, Gandrud Pickett L, Parks L, Spanakis EK, Masharani U, Akturk HK, Melish JS, Kim S, Kang GE, Klonoff DC. Diabetes Technology Meeting 2021. J Diabetes Sci Technol. 2022 07; 16(4):1016-1056.
    View in: PubMed
    Score: 0.055
  75. Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022 03 01; 45(3):750-753.
    View in: PubMed
    Score: 0.054
  76. Garg SK, Kipnes M, Castorino K, Bailey TS, Akturk HK, Welsh JB, Christiansen MP, Balo AK, Brown SA, Reid JL, Beck SE. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022 06; 24(6):373-380.
    View in: PubMed
    Score: 0.054
  77. Garg SK, Liljenquist D, Bode B, Christiansen MP, Bailey TS, Brazg RL, Denham DS, Chang AR, Akturk HK, Dehennis A, Tweden KS, Kaufman FR. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technol Ther. 2022 02; 24(2):84-92.
    View in: PubMed
    Score: 0.052
  78. Shah VN, Akturk HK, Joseph H, Schneider N, Snell-Bergeon JK. A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec. Diabetes Obes Metab. 2021 08; 23(8):1936-1941.
    View in: PubMed
    Score: 0.052
  79. Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell-Bergeon J, Driscoll KA, Forlenza GP. Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. Diabetes Obes Metab. 2021 09; 23(9):2048-2057.
    View in: PubMed
    Score: 0.051
  80. Barnard-Kelly KD, Naranjo D, Majidi S, Akturk HK, Breton M, Courtet P, Olié E, Lal RA, Johnson N, Renard E. Suicide and Self-inflicted Injury in Diabetes: A Balancing Act. J Diabetes Sci Technol. 2020 11; 14(6):1010-1016.
    View in: PubMed
    Score: 0.046
  81. Kinney GL, Akturk HK, Taylor DD, Foster NC, Shah VN. Cannabis Use Is Associated With Increased Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Findings From the T1D Exchange Clinic Registry. Diabetes Care. 2020 01; 43(1):247-249.
    View in: PubMed
    Score: 0.046
  82. Kaur H, Schneider N, Pyle L, Campbell K, Akturk HK, Shah VN. Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis. Diabetes Technol Ther. 2019 12; 21(12):736-739.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)